Use of a targeted oncolytic poxvirus, JX-594, in patients with refractory primary or metastatic liver cancer: a phase I trial.

@article{Park2008UseOA,
  title={Use of a targeted oncolytic poxvirus, JX-594, in patients with refractory primary or metastatic liver cancer: a phase I trial.},
  author={Byeong Ho Park and Taeho Hwang and Ta-Chiang Liu and Daniel Y. Sze and Jae-seok Kim and Hyuk-Chan Kwon and Sung Yong Oh and S Han and Jin-Han Yoon and S Hong and Anne Moon and Kelly A. Speth and Chohee Park and Young-Joo Ahn and Manijeh Daneshmand and Byung Geon Rhee and Herbert M. Pinedo and John Cameron Bell and David H. Kirn},
  journal={The Lancet. Oncology},
  year={2008},
  volume={9 6},
  pages={533-42}
}
BACKGROUND JX-594 is a targeted oncolytic poxvirus designed to selectively replicate in and destroy cancer cells with cell-cycle abnormalities and epidermal growth factor receptor (EGFR)-ras pathway activation. Direct oncolysis plus granulocyte-macrophage colony-stimulating factor (GM-CSF) expression also stimulates shutdown of tumour vasculature and antitumoral immunity. We aimed to assess intratumoral injection of JX-594 in patients with refractory primary or metastatic liver cancer… CONTINUE READING
Highly Influential
This paper has highly influenced 12 other papers. REVIEW HIGHLY INFLUENTIAL CITATIONS
145 Citations
0 References
Similar Papers

Citations

Publications citing this paper.
Showing 1-10 of 145 extracted citations

Similar Papers

Loading similar papers…